Clinicopathological and molecular characterization of thoracic inflammatory myofibroblastic tumors: A single-center surgical series
Clinical Surgical Oncology · 2026-12 · 5 (4) · 100149
DOI: 10.1016/j.cson.2026.100149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Surgical Oncology, 2026-12. Verfasst von Luca Bertolaccini und 13 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Government Ministry of Health.
Abstract (Originalsprache)
Introduction
Inflammatory myofibroblastic tumor (IMT) is an extremely rare neoplasm, accounting for less than 0.2% of all lung lesions. We describe the clinicopathological characteristics, molecular features, and surgical outcomes of a single-center series of thoracic IMT.
Methods
This descriptive retrospective case series included 20 patients who underwent surgical resection for primary thoracic IMT between 1998 and 2025. Clinicopathological features were collected in accordance with the STROBE guidelines. Immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing were performed on surgical resection specimens. Analyses were conducted at the patient level and were descriptive; no comparative efficacy analysis was planned.
Results
The cohort included 8 men and 12 women, with a median age of 45 years (range, 13–72 years). All 20 patients underwent R0 resection. No postoperative deaths occurred, and 5 patients (25%) experienced postoperative complications. At a median postoperative follow-up of 114 months (range, 1–303 months), all patients were alive without local or distant recurrence. Among the 20 cases, 12 (60%) were positive for ALK by immunohistochemistry and/or fluorescence in situ hybridization. RNA-based next-generation sequencing was adequate in 8 cases and identified ALK fusions in 5; a ROS1 rearrangement was identified in one ALK-negative case.
Conclusions
In this selected series of localized, completely resected thoracic IMTs, all patients were alive and recurrence-free at last follow-up. Because this was a small descriptive case series without a comparator, no comparative conclusion regarding surgical efficacy can be drawn. ALK rearrangements were the most frequent molecular drivers detected. The ROS1-rearranged ALK-negative case illustrates the potential relevance of broader molecular profiling if unresectable or recurrent disease develops.
Förderung
- Italian Government Ministry of Health
Zitieren
APA
Bertolaccini, L., Lombardi, M., Luca, V. M. D., d’Ercole, M., Pescia, C., Vacirca, D., Conversano, F., Adorisio, R., Zanetti, C., Pessina, S., Caffarena, G., Fusco, N., Rocco, E. G., & Spaggiari, L. (2026). Clinicopathological and molecular characterization of thoracic inflammatory myofibroblastic tumors: A single-center surgical series. Clinical Surgical Oncology, 5(4), 100149. https://doi.org/10.1016/j.cson.2026.100149
Vancouver
Bertolaccini L, Lombardi M, Luca VMD, d’Ercole M, Pescia C, Vacirca D, et al. Clinicopathological and molecular characterization of thoracic inflammatory myofibroblastic tumors: A single-center surgical series. Clinical Surgical Oncology. 2026;5(4):100149. doi:10.1016/j.cson.2026.100149
BibTeX
@article{Bertolaccini2026,
author = {Bertolaccini, Luca and Lombardi, Mariano and Luca, Valeria Midolo De and d’Ercole, Marianna and Pescia, Carlo and Vacirca, Davide and Conversano, Federica and Adorisio, Riccardo and Zanetti, Chiara and Pessina, Simona and Caffarena, Giovanni and Fusco, Nicola and Rocco, Elena Guerini and Spaggiari, Lorenzo},
title = {Clinicopathological and molecular characterization of thoracic inflammatory myofibroblastic tumors: A single-center surgical series},
journal = {Clinical Surgical Oncology},
year = {2026},
volume = {5},
number = {4},
pages = {100149},
doi = {10.1016/j.cson.2026.100149}
}
EUVIMED